Cargando…

Hypophysitis induced by ipilimumab and nivolumab combination therapy for advanced renal cell carcinoma: A case report

Ipilimumab and nivolumab combination therapy is effective against unresectable or metastatic renal cell carcinoma. However, it is associated with many immune-related adverse events, including hypophysitis that is difficult to diagnose early because of non-specific initial symptoms. Herein, we report...

Descripción completa

Detalles Bibliográficos
Autores principales:	Motonaga, Aoi, Nakanishi, Shotaro, Tanaka, Kei, Nishida, Sho, Izumi, Keiichiro, Saito, Seiichi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8040277/ https://www.ncbi.nlm.nih.gov/pubmed/33868946 http://dx.doi.org/10.1016/j.eucr.2021.101661

Ejemplares similares

A case report of nivolumab-induced myasthenia gravis and myositis in a metastatic renal cell carcinoma patient
por: Nakanishi, Shotaro, et al.
Publicado: (2019)

Nivolumab Combined With Ipilimumab Treatment Induced Hypophysitis and Immune-Mediated Liver Injury in Advanced Esophageal Squamous Cell Carcinoma: A Case Report
por: Feng, Yi, et al.
Publicado: (2022)

FRI331 Autoimmune Hypophysitis Secondary To Ipilimumab And Nivolumab Combination Therapy In A Patient With Advanced Renal Cell Carcinoma
por: Ibrahim, Eiman Y, et al.
Publicado: (2023)

Efficacy and toxicity of Ipilimumab-Nivolumab combination therapy in elderly metastatic melanoma patients
por: Stoff, Ronen, et al.
Publicado: (2022)

Myocarditis and myasthenia gravis by combined nivolumab and ipilimumab immunotherapy for renal cell carcinoma: A case report of successful management
por: Yanase, Takahiro, et al.
Publicado: (2020)

Healthcare cost comparison analysis of nivolumab in combination with ipilimumab versus nivolumab monotherapy and ipilimumab monotherapy in advanced melanoma
por: Potluri, Ravi, et al.
Publicado: (2019)

Development of Extragenital Lichen Sclerosus in Malignant Melanoma Patients Treated With Ipilimumab in Combination With Nivolumab
por: Seyed Jafari, S. Morteza, et al.
Publicado: (2020)

Ipilimumab (Immune Checkpoint Inhibitors) Hypophysitis
por: Stagnetto, Margot, et al.
Publicado: (2020)

Clinical implications of the tumor microenvironment using multiplexed immunohistochemistry in patients with advanced or metastatic renal cell carcinoma treated with nivolumab plus ipilimumab
por: Kim, Jwa Hoon, et al.
Publicado: (2022)

Cost-Effectiveness of Nivolumab Plus Ipilimumab With and Without Chemotherapy for Advanced Non-Small Cell Lung Cancer
por: Yang, Szu-Chun, et al.
Publicado: (2021)

Ipilimumab cystic hypophysitis mimicking metastatic melanoma
por: Wallace, John, et al.
Publicado: (2018)

SUN-416 Ipilimumab Associated Hypophysitis and Thyroiditis
por: Kazi, Fatima, et al.
Publicado: (2019)

Case Report: Response to ipilimumab and nivolumab in a patient with adrenocortical carcinoma
por: Charles, Rebecca, et al.
Publicado: (2023)

Population Pharmacokinetics of Nivolumab in Combination With Ipilimumab in Patients With Advanced Malignancies
por: Zhang, Jason, et al.
Publicado: (2019)

Case Report: Complete Response of Recurrent and Metastatic Cystadenocarcinoma of the Parotid Gland With a Single Course of Combined Nivolumab and Ipilimumab Therapy
por: Nakamura, Yoshiyuki, et al.
Publicado: (2021)

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma
por: Wolchok, Jedd D., et al.
Publicado: (2022)

Case Report: Neuromyelitis Optica After Treatment of Uveal Melanoma With Nivolumab and Ipilimumab
por: Khimani, Karima, et al.
Publicado: (2022)

Long Term Remission and Cardiac Toxicity of a Combination of Ipilimumab and Nivolumab in a Patient With Metastatic Head and Neck Carcinoma After Progression Following Nivolumab Monotherapy
por: Schwab, Katjana S., et al.
Publicado: (2019)

Safety and efficacy of first-line nivolumab plus ipilimumab alternating with nivolumab monotherapy in patients with advanced renal cell carcinoma: the non-randomised, open-label, phase IIIb/IV CheckMate 920 trial
por: George, Daniel J, et al.
Publicado: (2022)

Nivolumab plus ipilimumab in the treatment of advanced melanoma
por: Tsai, Katy K., et al.
Publicado: (2015)

Population Pharmacokinetics of Ipilimumab in Combination With Nivolumab in Patients With Advanced Solid Tumors
por: Sanghavi, Kinjal, et al.
Publicado: (2019)

Potential Immune-Related Adverse Events Associated With Monotherapy and Combination Therapy of Ipilimumab, Nivolumab, and Pembrolizumab for Advanced Melanoma: A Systematic Review and Meta-Analysis
por: Almutairi, Abdulaali R., et al.
Publicado: (2020)

Case Report: Differential Genomics and Evolution of a Meningeal Melanoma Treated With Ipilimumab and Nivolumab
por: Burgos, Remberto, et al.
Publicado: (2022)

Risk of Adverse Events in Cancer Patients Receiving Nivolumab With Ipilimumab: A Meta-Analysis
por: Zhao, Xin, et al.
Publicado: (2022)

Nivolumab plus ipilimumab in metastatic melanoma: a critical appraisal focused on specific subpopulations
por: Vázquez-Montero, Lucía, et al.
Publicado: (2023)

Thyroid storm induced by combined nivolumab and ipilimumab immunotherapy in advanced non-small cell lung cancer
por: Kataoka, Shunichi, et al.
Publicado: (2022)

Prognostic Value of Absolute Lymphocyte Count in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab plus Ipilimumab
por: Ueda, Kosuke, et al.
Publicado: (2023)

Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
por: Chapman, Paul B, et al.
Publicado: (2021)

Early Response Assessment in Advanced Stage Melanoma Treated with Combination Ipilimumab/Nivolumab
por: Ma, Vincent T., et al.
Publicado: (2022)

Managing Ipilimumab-Induced Hypophysitis: Challenges and Current Therapeutic Strategies
por: Tsoli, Marina, et al.
Publicado: (2020)

Complete response of metastatic renal cell carcinoma with inferior vena cava tumor thrombus to nivolumab plus ipilimumab
por: Hayashida, Michikata, et al.
Publicado: (2022)

Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab vs. Chemotherapy as First-Line Therapy in Advanced Non-Small Cell Lung Cancer
por: Hu, Huabin, et al.
Publicado: (2020)

Case Report: Durable complete pathologic response and organ preservation following ipilimumab and nivolumab for locally advanced primary vaginal mucosal melanoma
por: Tarhini, Ahmad A., et al.
Publicado: (2022)

Adverse events induced by nivolumab and ipilimumab combination regimens
por: Somekawa, Kohei, et al.
Publicado: (2022)

Combined Nivolumab and Ipilimumab in Octogenarian and Nonagenarian Melanoma Patients
por: Reichert, Constance, et al.
Publicado: (2023)

Severe Gastritis after Administration of Nivolumab and Ipilimumab
por: Nishimura, Yoshito, et al.
Publicado: (2018)

Case Report: Exceptional Response to Nivolumab Plus Ipilimumab in a Young Woman With TFE3-SFPQ Fusion Translocation-Associated Renal Cell Carcinoma
por: Martini, Dylan J., et al.
Publicado: (2021)

Efficacy and Safety of Nivolumab and Ipilimumab for Advanced or Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Cohort Study
por: Iinuma, Koji, et al.
Publicado: (2021)

REchallenge of NIVOlumab (RENIVO) or Nivolumab-Ipilimumab in Metastatic Renal Cell Carcinoma: An Ambispective Multicenter Study
por: Vauchier, Charles, et al.
Publicado: (2022)

Ipilimumab-induced autoimmune hypophysitis: a differential for sellar mass lesions
por: Rodrigues, Beverly T, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_pm4n5tqgsuvjlcb1khbhji3isj